Trial Outcomes & Findings for Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) (NCT NCT00673439)

Results Overview

Clinically significant bleed is defined as Hemodynamically Significant Bleeding or Requiring Blood Transfusions While Being Treated With Fondaparinux

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

3 participants

Primary outcome timeframe

4 weeks after INR reaches 2 or more

Results posted on

2019-11-08

Participant milestones
Measure	Fondaparinux daily subcutaneous injection of fondaparinux (7.5-10 mg)
Overall Study STARTED	3
Overall Study COMPLETED	3
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Baseline characteristics by cohort
Measure	Fondaparinux n=3 Participants daily subcutaneous injection of fondaparinux (7.5-10 mg)
Age, Customized Over 18 years of age	3 Participants n=5 Participants
Sex: Female, Male Female	2 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants

Timeframe: 4 weeks after INR reaches 2 or more

Clinically significant bleed is defined as Hemodynamically Significant Bleeding or Requiring Blood Transfusions While Being Treated With Fondaparinux

Outcome measures
Measure	Fondaparinux n=3 Participants daily subcutaneous injection of fondaparinux (7.5-10 mg)
Number of Participants Showing Clinically Significant Bleeding	0 participants

Timeframe: 4 weeks after INR reaches 2 or more

Outcome measures
Measure	Fondaparinux n=3 Participants daily subcutaneous injection of fondaparinux (7.5-10 mg)
the Incidence of Venous or Thrombotic Events After Starting Treatment With Fondaparinux	0 Participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

James Graham Brown Cancer Center

Phone: 502/562-4358